Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 11/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13721080 | 0.88 | ALDH1A1 (0.40) | VCPTSHRALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3981433 | 0.86 | LMNA (0.44) | VCPTSHRALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL2544522 | 0.81 | ALDH1A1 (0.42) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL1333153 | 0.76 | ALDH1A1 (0.40) | TSHRALDH1A1HPGDSMN1; SMN2NPC1 | |
| SCHEMBL7904174 | 0.76 | ALDH1A1 (0.40) | TSHRALDH1A1GAAHPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3980796 | 0.75 | ALDH1A1 (0.39) | TSHRALDH1A1HPGDSMN1; SMN2NPC1 | |
| SCHEMBL19949182 | 0.72 | CYP2C19 (0.39) | TSHRALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL13469345 | 0.72 | CYP2C19 (0.42) | TSHRALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1485370 | 0.68 | CYP2C19 (0.38) | TSHRALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL12864677 | 0.67 | MEN1 (0.65) | TSHRSMN1; SMN2NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379558-B1 | NOVEL HETEROCYCLIC COMPOUNDS FOR USE AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-03-23 | — | — | EP | disclosed |
| US-8546406-B2 | Heterocyclic compounds as metap-2 inhibitors | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546406-B2 | Heterocyclic compounds as metap-2 inhibitors | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-17 | — | — | US | disclosed |
| WO-2010083870-A1 | NOVEL HETEROCYCLIC COMPOUNDS FOR USE AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | METAP2, METAP1, XPNPEP2 | VCP 3059/4885TSHR 1740/4885ALDH1A1 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.